Analytical and Bioanalytical Chemistry

, Volume 398, Issue 7–8, pp 3051–3061 | Cite as

Raman chemical mapping reveals site of action of HIV protease inhibitors in HPV16 E6 expressing cervical carcinoma cells

  • Dong-Hyun Kim
  • Roger M. Jarvis
  • J. William Allwood
  • Gavin Batman
  • Rowan E. Moore
  • Emma Marsden-Edwards
  • Lynne Hampson
  • Ian N. Hampson
  • Royston Goodacre
Original Paper

Abstract

It has been shown that the HIV protease inhibitors indinavir and lopinavir may have activity against the human papilloma virus (HPV) type 16 inhibiting HPV E6-mediated proteasomal degradation of p53 in cultured cervical carcinoma cells. However, their mode and site of action is unknown. HPV-negative C33A cervical carcinoma cells and the same cells stably transfected with E6 (C33AE6) were exposed to indinavir and lopinavir at concentrations of 1 mM and 30 μM, respectively. The intracellular distribution of metabolites and metabolic changes induced by these treatments were investigated by Raman microspectroscopic imaging combined with the analysis of cell fractionation products by liquid chromatography–mass spectrometry (LC-MS). A uniform cellular distribution of proteins was found in drug-treated cells irrespective of cell type. Indinavir was observed to co-localise with nucleic acid in the nucleus, but only in E6 expressing cells. Principal components analysis (PCA) score maps generated on the full Raman hypercube and the corresponding PCA loadings plots revealed that the majority of metabolic variations influenced by the drug exposure within the cells were associated with changes in nucleic acids. Analysis of cell fractionation products by LC-MS confirmed that the level of indinavir in nuclear extracts was approximately eight-fold greater than in the cytoplasm. These data demonstrate that indinavir undergoes enhanced nuclear accumulation in E6-expressing cells, which suggests that this is the most likely site of action for this compound against HPV.

Keywords

HPV Indinavir Lopinavir Raman chemical mapping LC-MS 

Notes

Acknowledgements

This research was funded by an ORS award to D-H.K. R.M.J. is very thankful to the UK BBSRC for funding. J.W.A., E.M.-E. and R.G. are grateful to the EU-funded project, Metabolomics for Plants Health and OutReach (META-PHOR: FOOD-CT-2006-036220), for financial support. R.G. is grateful to both the UK BBSRC and EPSRC for financial support of the MCISB. The authors also acknowledge the support of the Humane Research Trust, the Caring Cancer Research Trust and Cancer Research UK.

Disclosure statement

The authors have no conflict of interest

Supplementary material

216_2010_4283_MOESM1_ESM.pdf (480 kb)
Fig. S1 The microscope offers focussing and data collecting optics for both spectral and white light images from the cell. After the Raman spectrum is collected from the first point, the incident light is moved in a raster pattern across the grid in a diffraction-limited spot size (1 × 1 μm), then another spectrum is taken. This process is continued until the area of the cell assigned by the operator has been covered (PDF 480 kb)

References

  1. 1.
    zur Hausen H (1996) Papillomavirus infections—a major cause of human cancers. Biochim Biophys Acta 1288:55–78Google Scholar
  2. 2.
    de Villiers EM (1989) Heterogeneity of the human papillomavirus group. J Virol 63:4898Google Scholar
  3. 3.
    Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The e6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129–1136CrossRefGoogle Scholar
  4. 4.
    Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G (2004) Efficacy of a bivalent l1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 346:1757–1765CrossRefGoogle Scholar
  5. 5.
    Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJF, Meijer CJLM (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527CrossRefGoogle Scholar
  6. 6.
    Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett RM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Essser MT, Sings HL, Saah AJ, Barr E (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271–278CrossRefGoogle Scholar
  7. 7.
    Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E (2006) Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 367:489–498CrossRefGoogle Scholar
  8. 8.
    zur Hausen H (2000) Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92:690–698CrossRefGoogle Scholar
  9. 9.
    Hampson L, Kitchener HC, Hampson IN (2006) Specific HIV protease inhibitors inhibit the ability of hpv16 e6 to degrade p53 and selectively kill e6-dependent cervical carcinoma cells in vitro. Antivir Ther 11:813–825Google Scholar
  10. 10.
    Kim D-H, Jarvis RM, Xu Y, Oliver AW, Allwood JW, Hampson L, Hampson IN, Goodacre R (2010) Combining metabolic fingerprinting and footprinting to understand the phenotypic response of hpv16 e6 expressing cervical carcinoma cells exposed to the hiv anti-viral drug lopinavir. Analyst 135:1235–1244CrossRefGoogle Scholar
  11. 11.
    Chow WA, Jiang C, Guan M (2009) Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol 10:61–71CrossRefGoogle Scholar
  12. 12.
    Hampson L, El Hady E, Moore JV, Kitchener H, Hampson IN (2001) The HPV16 e6 and e7 proteins and the radiation resistance of cervical carcinoma. FASEB J 15:1445–1447Google Scholar
  13. 13.
    Wold H (1966) Multivariate analysis. Academic, New YorkGoogle Scholar
  14. 14.
    Jolliffe IT (1986) Principal component analysis. Springer, New YorkGoogle Scholar
  15. 15.
    Sumner LW, Mendes P, Dixon RA (2003) Plant metabolomics: large-scale phytochemistry in the functional genomics era. Phytochemistry 62:817–836CrossRefGoogle Scholar
  16. 16.
    Laemmli UK (1986) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685CrossRefGoogle Scholar
  17. 17.
    Wrona M, Mauriala T, Bateman KP, Mortishire Smith RJ, O'Connor D (2005) All-in-one analysis for metabolite identification using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry with collision energy switching. Rapid Commun Mass Spectrom 19:2597–2602CrossRefGoogle Scholar
  18. 18.
    Bateman KP, Castro-Perez J, Wrona M, Shockcor JP, Yu K, Oballa R, Nicoll-Griffith DA (2007) Mse with mass defect filtering for in vitro and in vivo metabolite identification. Rapid Commun Mass Spectrom 2:1485–1496CrossRefGoogle Scholar
  19. 19.
    Banks L, Pim D, Thomas M (2003) Viruses and the 26S proteasome: hacking into destruction. Trends Biochem Sci 28:452–459CrossRefGoogle Scholar
  20. 20.
    Mantovani F, Banks L (1999) The interaction between p53 and papillomaviruses. Semin Cancer Biol 9:387–395CrossRefGoogle Scholar
  21. 21.
    Allwood JW, Goodacre R (2010) An introduction to liquid chromatography–mass spectrometry instrumentation applied in plant metabolomic analyses. Phytochem Anal 21:33–47CrossRefGoogle Scholar
  22. 22.
    Ellis DI, Goodacre R (2006) Metabolic fingerprinting in disease diagnosis: biomedical applications of infrared and Raman spectroscopy. Analyst 131:875–885CrossRefGoogle Scholar
  23. 23.
    Clark D, Sasic S (2006) Chemical images: technical approaches and issues. CytometryA 69a:815–824CrossRefGoogle Scholar
  24. 24.
    Buschman HP, Deinum G, Morz JT, Fizmaurice M, Kramer JR, van der Laarse A, Bruschke AV, Feld MS (2001) Raman microspectroscopy of human coronary atherosclerosis: biochemical assessment of cellular and extracellular morphologic structures in situ. Cardiovasc Pathol 10:69–82CrossRefGoogle Scholar
  25. 25.
    Harris AT, Lungari A, Needham CJ, Smith SL, Lones MA, Fisher SE, Yang XB, Cooper N, Kirkham J, Smith DA, Martin-Hirsch DP, High AS (2009) Potential for Raman spectroscopy to provide cancer screening using a peripheral blood sample. Head Neck Oncol 1:34–41CrossRefGoogle Scholar
  26. 26.
    Hawi SR, Campbell WB, Balla AK, Murphy R (1996) Characterization of normal and malignant human hepatocytes by Raman microspectroscopy. Cancer Lett 110:35–40CrossRefGoogle Scholar
  27. 27.
    Shafer-Peltier KE, Haka AS, Fitzmaurice M, Crowe J, Myles J, Dasari RR, Feld MS (2002) Raman microspectroscopic model of human breast tissue: implications for breast cancer diagnosis in vivo. J Raman Spectrosc 33:552–563CrossRefGoogle Scholar
  28. 28.
    Ellis EI, Dunn WB, Griffin JL, Allwood JW, Goodacre R (2007) Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics 8:1243–1266CrossRefGoogle Scholar
  29. 29.
    Mahadevan-Jansen A, Richards-Kortum R (1997) Raman spectroscopy for cancer detection: a review. Conf Proc IEEE Eng Med Biol Soc 6:2722–2728Google Scholar
  30. 30.
    Beljebbar A, Sockalingum GD, Morjani H, Manfait M (1999) Raman and sers microspectroscopy on living cells: a promising tool towards cellular-drug response and medical diagnosis. Proc SPIE 3608:175–184CrossRefGoogle Scholar
  31. 31.
    Kang E, Wang H, Kwon IK, Robinson J, Park K, Cheng JX (2006) In situ visualization of paclitaxel distribution and release by coherent anti-stokes Raman scattering microscopy. Anal Chem 78:8036–8043CrossRefGoogle Scholar
  32. 32.
    Short KW, Carpenter S, Freyer JP, Mourant JR (2005) Raman spectroscopy detects biochemical changes due to proliferation in mammalian cell cutures. Biophys J 88:4274–4288CrossRefGoogle Scholar
  33. 33.
    Uzunbajakava N, Lenferink A, Kraan Y, Willekens B, Vrensen G, Greve J, Otto C (2003) Nonresonant raman imaging of protein distribution in single human cells. Biopolymers 72:1–9CrossRefGoogle Scholar
  34. 34.
    Wan F, Miao X, Quraishi I, Kennedy V, Creek KE, Pirisi L (2008) Gene expression changes during HPV-mediated carcinogenesis: a comparison between an in vitro cell model and cervical cancer. Int J Cancer 123:32–40CrossRefGoogle Scholar
  35. 35.
    Martin CM, Astbury K, McEvoy L, O'Toole S, Sheils O, O'Leary JJ (2009) Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy. Meth Mol Biol 511:333–359CrossRefGoogle Scholar
  36. 36.
    Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB (2004) Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol 22:245–252CrossRefGoogle Scholar
  37. 37.
    Faolain EO, Hunter MB, Byrne JM, Kelehan P, Byrne HJ, Lyng FM (2005) The potential of vibrational spectroscopy in the early detection of cervical cancer: an exciting emerging field. Proc SPIE 5826:25–36CrossRefGoogle Scholar
  38. 38.
    Notingher IN, Verrier S, Haque S, Polak JM, Hench LL (2003) Spectroscopic study of human lung epithelial cells (a549) in culture: living cells versus dead cells. Biopolymers 72:230–240CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Dong-Hyun Kim
    • 1
  • Roger M. Jarvis
    • 1
  • J. William Allwood
    • 1
  • Gavin Batman
    • 2
  • Rowan E. Moore
    • 3
  • Emma Marsden-Edwards
    • 3
  • Lynne Hampson
    • 2
  • Ian N. Hampson
    • 2
  • Royston Goodacre
    • 1
    • 4
  1. 1.School of Chemistry, Manchester Interdisciplinary BiocentreThe University of ManchesterManchesterUK
  2. 2.Gynaecological Oncology Laboratories, School of Cancer & Enabling Sciences, St Mary’s HospitalThe University of ManchesterManchesterUK
  3. 3.Waters CorporationManchesterUK
  4. 4.Manchester Centre for Integrative Systems Biology (MCISB), Manchester Interdisciplinary BiocentreThe University of ManchesterManchesterUK

Personalised recommendations